Table 4.

Comparison of study outcomes with outcomes of 4D Study

ParameterAdjusted [HR (95% CI)] (n = 9016)a4D Study [HR (95% CI)] (n = 1255)Pb
Primary outcome0.90 (0.82 to 0.97)0.92 (0.77 to 1.10)0.83
Death from cardiac causes0.83 (0.75 to 0.92)0.81 (0.64 to 1.03)0.85
Nonfatal MI0.92 (0.79 to 1.08)0.88 (0.64 to 1.21)0.81
Fatal stroke0.93 (0.64 to 1.35)2.03 (1.05 to 3.93)0.04
Nonfatal stroke1.25 (1.03 to 1.51)1.04 (0.64 to 1.69)0.49
All cardiac events combined0.90 (0.83 to 0.98)0.82 (0.68 to 0.99)0.37
All cerebrovascular events (stroke and TIA)1.15 (0.97 to 1.36)1.12 (0.81 to 1.55)0.89
    Fatal and nonfatal strokes1.16 (0.97 to 1.39)1.33 (0.90 to 1.97)0.53
Death from all causes0.82 (0.76 to 0.89)0.93 (0.79 to 1.08)0.17
Death but not from CVA or CAD0.80 (0.70 to 0.91)0.95 (0.76 to 1.18)0.20
  • CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebrovascular event; TIA, transient ischemic attack.

  • a Model adjusted for age, gender, race (white, black, or other), vintage, total cholesterol, Charlson comorbidity index (diabetes, MI, CHF, stroke, peptic ulcer disease, cancer with or without metastasis, liver disease, hemiplegia, dementia, peptic ulcer disease, chronic lung disease, connective tissue disease, peripheral vascular disease, AIDS), other comorbidity (hypertension, atrial fibrillation, CAD, past infection, previous hospitalization for chest pain, amputation, vascular disease), dialysis adequacy, epogen dosage, vitamin D use, access (fistula, graft, catheter, or unknown), body mass index, fasting blood glucose, baseline laboratory values (hemoglobin, albumin, white blood cell count, ferritin, calcium, phosphorus, parathyroid hormone), cardiovascular medication (angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, warfarin, β blocker, clopidogrel, digoxin, aspirin), BP (systolic and diastolic), and propensity score.

  • b P value comparing the hazard ratio of the adjusted analysis and the HR reported in the 4D Study.